take one deal away real pipelin
move past hcv worst behind us like
compani set expect net product sale roughli
expect hcv sale dramat less signific portion
total product sale expect street estim
higher expect view guidanc
like conserv reason market share steadi state time
biggest move piec hiv continu believ bictegravir
goat hiv launch estim sale vs
consensu yescarta sale slightli better
expect sound compani make continu progress
launch phase center us new hiv estim
vs previous previous model decreas
ex-u hiv busi relat gener total product revenu
ep vs prior revenu ep
new ep
respect multipl unreason
pipelin come greater scope compar larg cap peer
multipl certainli post think gilead back
growth path model year ep compound-annual-growth-rate
think launch yescarta across mani hematolog condit
pipelin product launch next year nash
filgotinib addit potenti acquisit stori return
back growth
risk neutral rate target price includ greater
expect competit commerci headwind hiv car-t space
pipelin setback failur
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
gilead biotechnolog compani focus develop
commerci antivir treatment product includ
sovaldi harvoni hepat stribild complera/eviplera
atripla truvad viread hiv
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
sky scenario model probabl success
yescarta expans well filgotanib nash maintain
base case third line yescarta hiv hcv sale
grey sky scenario model car-t platform
success beyond dlbcl filgotanib nash
program fail maintain base case third line yescarta hiv
hcv sale
 close
expect gilead activ make transform acquisit
year would make us bullish compani build
enhanc expertis cellular therapi believ increas comfort
level adjac therapi cellular therapi think could take
shape interest gene therapi gene edit think bluebirdbio could
interest synergi gilead current abil cellular therapi gilead
cash end adjust debt ebitda still remain reason
year-end
speak manag think less interest build
io space unless find modal io gilead
antibodi capabl california could make asset io
space view far behind rel commodit
point need like sound like could buy earlier phase
compound sinc mani develop
reason credit
dcf non-oncolog pipelin
opportun includ nash filgotinib think manag remain
bullish program get nash data cirrhot patient
like see fxr data gut restrict fxr agonist
upcom medic meet perhap easl see data glpg
drug filgotinib rheumatoid arthriti assum
sale nash franchis filgotinib respect probabl adjust
near bottom
compani mention price
